Clinical trial · Interventional
Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)
Correlation of Contrast Enhanced Ultrasound of Renal Masses With Pathologic Grade: A Prospective Comparison of Quantitative and Qualitative Findings
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study stopped due to staffing issues that impacted ability to recruit.
Summary
Brief summary (as posted)
Patients with renal lesions suspicious for renal cell carcinoma (RCC) have a variety of different treatment pathways available to them. Imaging surveillance is being used frequently on smaller renal masses, and radiologists are being asked to biopsy more renal lesions to better guide decision making by urology. This is in large part due to the pathologic grade of renal masses having been shown to correlate with patient outcomes. The World Health Organization (WHO) or Fuhrman grade is the standard grading scale used by pathologists for RCC. The goal of this study will be to correlate contrast enhanced ultrasound findings with the pathologic grade of RCC. Specifically, the investigators hypothesize that tumors with different pathologic grades will show different patterns of qualitative enhancement, as well as different perfusion kinetics.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Malignant Tumor | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Contrast enhanced ultrasound with Lumason | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Renal malignancy
- description
- Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason
- interventionNames
- Drug: Contrast enhanced ultrasound with Lumason
Primary outcomes (2)
- measure
- Contrast Enhanced Ultrasound Features of Renal Masses (Time to Peak, Mean Transit Time)
- timeFrame
- 6 months
- description
- Ultrasound images will be reviewed for quantitative post contrast features (time to peak, mean transit time)
- measure
- Contrast Enhanced Ultrasound Features of Renal Masses (Peak Intensity)
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Greater than or equal to 18 years of age * Previously identified renal mass with radiology and clinical features consistent with RCC * Clinical care plan includes partial or total nephrectomy Exclusion Criteria: * Less than 18 years of age * Currently pregnant * Renal mass with clinical care plan that does not include nephrectomy * Renal mass suspected to be non RCC neoplasm by imaging and clinical data * Renal mass unable to be visualized by grayscale ultrasound * Known renal vein thrombosis
References
Publications (0)
Data not yet available